Abstract
Whether adjuvant immune checkpoint inhibition cuts recurrence risk in patients with localized renal cell carcinoma, as the phase III KEYNOTE-564 study showed, is unclear. Three other adjuvant trials-CheckMate-914, IMmotion010, and PROSPER-recently reported no disease-free survival improvement, casting some doubt on the utility of this approach.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
